The prognostic role of preoperative chromogranin A expression in prostate cancer after radical prostatectomy

Arch Ital Urol Androl. 2012 Mar;84(1):17-21.

Abstract

Purposes: The aim was to analyze the prognostic role of preoperative chromogranin A CgA) as a marker of poor prognosis and recurrence after radical prostatectomy (RP) and to find a correlation with the other well known prognostic variables.

Materials and methods: This study comprises 306 patients with prostate cancer prospectively recruited who underwent RP from between 2000 and 2005. A blood sample for the determination of serum preoperative CgA value was obtained in all cases. Spearman correlation test was used to compare CgA to other variables, Kruskal-Wallis test to analyze CgA differences among > or = 3 groups (PSA, GS, Stage), Mann-Whitney test for 2 grouping variables. Survival analysis was estimated by Kaplan-Meier method, log-rank test to estimate differences among the analyzed variables.

Results: Median CgA level was 68 ng/ml. Correlation between age and CgA levels was positive and statistically significant (p < 0.001). Patient were divided in 2 groups based on median age.The difference was statistically significant (p = 0.002). Comparison of CgA among patients grouped according to other variables and patient stratified on normal (123 ng/ml) and cut-off value (68 ng/ml) of CgA did not achieve significant risk stratification.

Conclusion: Studies on a possible prognostic role of CgA have provided conflicting results. In our series we found a significant positive correlation between CgA and age, but no significant statistical correlation with other available variables analyzed.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Aged
  • Biomarkers, Tumor / blood*
  • Chromogranin A / blood*
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Predictive Value of Tests
  • Preoperative Care*
  • Prognosis
  • Prospective Studies
  • Prostatectomy* / methods
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / surgery*
  • Risk Assessment
  • Risk Factors
  • Sensitivity and Specificity
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Chromogranin A